Skip to content

In the BioHarmony Drug Report Database

Darifenacin hydrobromide

Enablex, Emselex (darifenacin hydrobromide) is a small molecule pharmaceutical. Darifenacin hydrobromide was first approved as Enablex on 2004-10-22. It is used to treat overactive urinary bladder and urge urinary incontinence in the USA. It has been approved in Europe to treat overactive urinary bladder and urge urinary incontinence. It is known to target muscarinic acetylcholine receptor M1 and muscarinic acetylcholine receptor M3.
Trade Name Emselex
Common Name Darifenacin hydrobromide
Indication overactive urinary bladder, urge urinary incontinence
Drug Class Muscarinic receptor antagonists
Darifenacin hydrobromide
Get full access now